These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 35120656)

  • 41. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
    Panés J; Vermeire S; D'Haens GR; Danese S; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravatà I; Gaya DR; Peyrin-Biroulet L; Dignass A;
    United European Gastroenterol J; 2023 Jun; 11(5):410-422. PubMed ID: 37139642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
    Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
    Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
    Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
    Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shooting for the Stars: Review of the STARDUST Trial and the Treat-to-Target Approach for Crohn's Disease.
    Shawn G; Hou JK
    Gastroenterol Hepatol (N Y); 2022 May; 18(5):243-247. PubMed ID: 36397755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
    Colombel JF; Sands BE; Gasink C; Yeager B; Adedokun OJ; Izanec J; Ma T; Gao LL; Lee SD; Targan SR; Ghosh S; Hanauer SB; Sandborn WJ
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):144-153.e2. PubMed ID: 37391056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
    Sandborn WJ; Rebuck R; Wang Y; Zou B; Adedokun OJ; Gasink C; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG; Lynch JP
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):578-590.e4. PubMed ID: 33618023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crohn's disease management after intestinal resection: a randomised trial.
    De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Gibson PR; Sparrow M; Leong RW; Florin TH; Gearry RB; Radford-Smith G; Macrae FA; Debinski H; Selby W; Kronborg I; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
    Lancet; 2015 Apr; 385(9976):1406-17. PubMed ID: 25542620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
    Koehm M; Rossmanith T; Foldenauer AC; Herrmann E; Brandt-Jürgens J; Burmester GR; Kellner H; Kiltz U; Kofler DM; Rech J; Mojtahed-Poor S; Jonetzko C; Burkhardt H; Behrens F;
    Lancet Rheumatol; 2023 Jan; 5(1):e14-e23. PubMed ID: 38251504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Kopylov U; Hanzel J; Liefferinckx C; De Marco D; Imperatore N; Plevris N; Baston-Rey I; Harris RJ; Truyens M; Domislovic V; Vavricka S; Biemans V; Myers S; Sebastian S; Ben-Horin S; González Lama Y; Gilletta C; Ariella BS; Zelinkova Z; Weisshof R; Storan D; Zittan E; Farkas K; Molnar T; Franchimont D; Cremer A; Afif W; Castiglione F; Lees C; Barreiro-de Acosta M; Lobaton T; Doherty G; Krznaric Z; Pierik M; Hoentjen F; Drobne D
    Aliment Pharmacol Ther; 2020 Jul; 52(1):135-142. PubMed ID: 32412134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.